(A051103) A Phase I Study Of RITUXIMAB, LENALIDOMIDE, And IBRUTINIB In Previously Untreated Follicular Lymphoma
Description: 

To determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab in previously untreated follicular lymphoma.

Study Number: 

NCG 242213

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01829568

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.